One dose of Sanofi Pasteur's H1N1 vaccine fails to provide children with seroprotection
This article was originally published in Scrip
Executive Summary
Sanofi-Pasteur's US approved pandemic H1N1 influenza vaccine does not provide children with seroprotection after one dose, show interim data from a US paediatric trial. Further results are awaited for the effect of the two-dose schedule, which is the basis of the product's licence.